 | ||
Fields Osteopathic MedicineImmunology Alma mater Phillips UniversityCollege of Osteopathic Medicine at Oklahoma State University Center for Health Sciences Known for Chief of the Clinical Trials Program at NIAIDLed the first human trial to test the Ebola vaccine Institution National Institute of Allergy and Infectious Diseases | ||
Julie E. Ledgerwood is an American allergist and immunologist, who serves as Chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Contents
Dr. Ledgerwood leads clinical trials and clinical collaborations for the VRC; and has served as Principal Investigator, Protocol Chair, or Associate Investigator for over 35 Phase I and II IND clinical trials studying vaccines and monoclonal antibodies targeting HIV, influenza, Ebola, malaria, Chikungunya, and other emerging infectious diseases. She led the first human trial aimed at testing a vaccine for Ebola virus.
Education
Dr. Ledgerwood graduated from Phillips University in Enid, Oklahoma and received her Doctor of Osteopathic Medicine degree from the College of Osteopathic Medicine at Oklahoma State University Center for Health Sciences.
Career
From 1999-2002, Dr. Ledgerwood completed her medical residency in internal medicine at Johns Hopkins Bayview Medical Center in Baltimore, Maryland. In 2002, Dr. Ledgerwood joined NIAID as a clinical fellow in allergy and immunology. In 2003, she joined the VRC as a clinical investigator. Dr. Ledgerwood is by the American Board of Allergy and Immunology.
Her work has been covered extensively in lay and scientific media outlets, including NBC News, Politico, The Guardian, NPR, and The New York Times.